Science & Technology

Graphic above shows Bluff Point Road watershed in blue and proposed rain gardens in green. Graphic from Nelson Pope Voorhis

On March 16, environmental advocates met with public officials at the Northport Yacht Club to announce the addition of four rain gardens along Northport Harbor.

Adrienne Esposito, executive director of Citizens Campaign for the Environment, said her organization has partnered with the Village of Northport and the yacht club to address water pollution. According to her, rain gardens are a cost-effective and simple way to protect the harbor.

“In short, a rain garden is a nature-based solution to man-made pollution,” she said. “Stormwater runoff carries with it pesticides and fertilizers and other pollution and contaminants into our surface waters across Long Island. This rain garden is very important because it will be removing thousands of gallons of rain before it goes into the harbor.”

Nelson Pope Voorhis, a Melville-based engineering firm, is making this vision a reality. According to Rusty Schmidt, landscape ecologist at Nelson Pope, the proposed rain gardens will act as a filtration system, flushing out debris and other sources of pollution, to discharge stormwater safely into the harbor.

“A rain garden is a shallow bowl that we put into the landscape and that we direct water to on purpose,” Schmidt said. “In this case, the water is going to be coming from Bluff Point Road, and as the water comes down the street it will go into these gardens first. That water will soak into the ground in one day or less — in this case it will probably soak in in a few hours because the soils are sandy — and that water will be cleansed and cleaned and get to a drinkable quality.” He added, “It’s still going out to Northport Harbor, but through the soil and without all the garbage.”

We once had a thriving, billion-dollar shellfish industry here on the Island, and this is an important measure to bring back those types of species.

— Assemblyman Keith Brown (R-Northport)

According to a study conducted by the U.S. Department of Agriculture, Northport Harbor and Northport Bay are both designated as priority waterbodies. Schmidt said that the proposed rain gardens would capture roughly 15,000 gallons of rainwater during a storm event, removing several harmful contaminants from the runoff before it reaches the harbor.

“Nitrogen is the number one pollutant to our bay, and we are eliminating a large volume of nitrogen from these rain gardens,” Schmidt said. “Nitrogen is the main component of growing the algal blooms, the red tides and the brown tides that are causing low oxygen and other problems in the harbor.”

The project is made possible by grants from the Long Island Sound Study and the National Fish and Wildlife Foundation’s Long Island Sound Futures Fund. Policymakers suggest this project will help to revitalize Northport’s decimated aquatic ecosystems.

“We once had a thriving, billion-dollar shellfish industry here on the Island, and this is an important measure to bring back those types of species,” said state Assemblyman Keith Brown (R-Northport). “I ran on a platform of cleaning up the Long Island Sound, the bays and the estuaries. The quality of them is a really important issue of mine, being from Northport.”

Ian Milligan, deputy village mayor and commissioner of Docks & Waterways, Police and Personnel, confirmed that the rain gardens near the yacht club will be the first of several planned to be installed throughout the village.

Local officials and environmentalists point to the site of a planned rain garden near Northport Yacht Club. Photo by Raymond Janis

“We have a huge runoff water problem here in Northport and it all ends up in the harbor,” Milligan said. “This is the first rain garden that we’re doing in Northport and I’m also happy to say that the village, through other grants and other programs, has three more that are going to be coming out this year.”

According to Esposito, these projects will lead to a cleaner, safer Northport Harbor.

“The bottom line is that this rain garden really will be a simple solution to rainwater pollution,” she said. “We will be using native plantings and taking an area right now that floods and reimagining that area as a beautiful garden that will be absorbing the rain and filtering those pollutants, thereby protecting the harbor.”

Esposito added that construction of the proposed rain gardens near Northport Yacht Club will begin this spring.

Dr. Henry Tannous during surgery. Photo from SBU

By Daniel Dunaief

While she hasn’t resolved the debate about two approaches to a type of heart surgery, Laurie Shroyer, Professor and Vice Chair for Research in the Department of Surgery at Stony Brook University’s Renaissance School of Medicine, has contributed considerable information over a long period of time.

Laurie Shroyer. Photo from SBU

In a recent study released in JAMA Surgery, Shroyer, who is the principal investigator and co-PIs Fred Grover and Brack Hattler of the Rocky Mountain Regional Affairs Medical Center, revealed that coronary artery bypass grafting had similar post-surgical death rates for the veterans in their study whether the surgeon used a heart-lung machine, called “on pump,” or performed the surgery without the machine, called “off pump.”

Using long-term results from 2,203 mostly men at 18 VA Centers in the Department of Veterans Affairs Randomized On/Off Bypass (ROOBY) trial, Shroyer determined that the death rate at 10 years was 34.2 percent for off-pump, compared with 31.1 percent for on-pump.

Patients typically need bypass graft surgery when they have a narrowing of their coronary arteries, which comes from fatty material accumulating in the walls of the arteries. Doctors take a part of a healthy blood vessel from the leg, wrist or elsewhere and bypass the blockage, building a detour for the blood and enabling better circulation in the heart.

Using the “off pump” procedure means doctors operate on a heart that’s still pumping blood through the body. The “on pump” procedure uses a heart lung machine to pump blood while the heart remains still.

While the results of this study don’t end the debate over whether one procedure is superior to another, doctors welcomed the data as a well-researched and detailed analysis.

“There’s always going to be this ever-last question of whether off versus on pump bypass surgery is better,” said Dr. Henry Tannous, Chief of Cardiothoracic Surgery at the Renaissance School of Medicine at Stony Brook University. “There’s always going to be very little nuances with different patients that will make us pick one or the other.”

Dr. Tannous who has performed the majority of all bypass surgeries at Stony Brook over the last five years, said the hospital offers surgeries with and without the pump. SB has doctors who specialize in each kind of bypass in case of a change in the expected procedure.

Doctors typically get a clear sense of whether a patient might benefit from on or off pump procedures before starting surgeries. In the great majority of cases, doctors perform the surgery according to their pre-planned expectations for the use of the pump.

Rarely, they convert to the other procedure based on inter operative findings that dictate the switch, Dr. Tannous explained.

Dr. Jorge Balauger, Associate Chief of Cardiothoracic Surgery and Director of Advanced Coronary Surgery, has performed 4,000 CABG procedures, including about 1,000 without the heart lung machine, or “off pump.”

In his considerable experience, he suggested that an 80-year old, who has renal or liver dysfunction and/or arteries in his or her neck that are partially blocked or had another type of comorbidity, such as something in the bone marrow, would not tolerate a heart lung machine well. A person with cirrhosis also would likely be better served with an off pump operation.

“Avoiding the heart lung machine on the older, sick patients is beneficial,” Dr. Balauger said, adding that he looks at the CABG procedure as being akin to a “tailor made suit” that has to fit the patient specifically.

In cases where patients need a second bypass procedure, Dr. Balauger also recommends off pump efforts because a second operation on pump is “way more complex” and requires “dissection of all the scar tissue around the heart, which makes it not only time consuming, but also risky.”

Dr. Henry Tannous. Photo from SBU

Dr. Tannous appreciates the perspective Shroyer brings to the discussion. “Sometimes, it’s an asset to have a researcher and statistician with a very scientifically oriented mind lead the study,” he said, adding that when surgeons meet with patients, they will discuss the use of the pump.

Dr. Baulager described the trial conducted by Shroyer as having an “excellent design” from a scientific standpoint.

He believed, however, that the study didn’t include surgeons who had sufficient expertise in off pump procedures. Dr. Baulager thought more experienced surgeons likely ensured better outcomes for off pump procedures.

One aspect of the study that was “refreshing” to Shroyer was how durable the surgical procedure is, with about 70 percent of patients who received this procedure, both on and off pump, still experiencing improvements in their pre-surgical chest pain symptoms after 10 years.

“We never expected the high proportion of patients would do so well longer term in terms of freedom from events, and in terms of symptoms,” she said. “The fact that the symptoms weren’t different between on and off pump is good news.”

After this type of study, Shroyer will work with several other trials to identify if certain sub-groups of high risk patients may have benefits from an off pump procedure.

To be sure, Shroyer cautioned that these results couldn’t be extrapolated to the general population, especially to women, as almost all of those the study followed were men.“Veterans are a unique population,” she said. “Many received cigarettes as part of their rations, and hypertension is quite high. They are a different population in terms of their [health care] complexities and their [underlying] illnesses.”

While the 10 year outcomes were similar, Shroyer found a shorter revascularization-free survival period among off pump patients. 

Dr. Tannous said this kind of study would generate considerable interest among cardiac surgeons.

“Everything [Shroyer] has written about bypass surgery from the ROOBY trials will catch any cardiac surgeon’s attention nationwide,” he said. “This paper is not any different. It has the extra long-term follow up that makes it more relevant.”

At the March 3 Town Board meeting, Councilwoman Jane Bonner recognized a group of Rocky Point High School Technology students who created a prosthetic hand for Anun Suastika, a six-year-old Indonesian boy who was born with no fingers on his right hand. Anan’s father made a plea on a website called E-name for someone to help make a prosthetic hand for his boy. 

Mr. Schumacher, passionate about teaching students the technology skills that they can use in many career fields, happened upon e-NABLE, an organization with volunteer members who use open-source technology and 3-D printers to provide free prosthetic hands for children and adults. He thought it would be a great way to blend technology and humanity into a project for his students and guided them as they built the prosthetic hand using the school’s 3-D printer. 

The students worked during free periods and after school to design and assemble the 3-D parts into a Phoenix V-3 prosthetic hand. As traditional prosthetics normally cost thousands of dollars and need to be replaced as children grow, the production of a printed Phoenix V-3 prosthetic hand is much more inexpensive because of its design: It simply relies on a person’s functional wrist and uses the palm to push against the device so the fingers close when the wrist is bent.

“It is not every day that high school students can make such a big impact on a person’s life, but these students did just that. I thank Mr. Schumacher and his Technology class for taking on the challenge to improve Anun’s quality of life,” said Councilwoman Jane Bonner. 

“We are grateful to Mr. Schumacher and these students for this project that will have a profound effect on a boy’s life,” Rocky Point School District Superintendent of Schools Dr. Scott O’Brien said. “The enthusiasm and passion shown by this committed group is inspiring to others in our school district, learning that in our classrooms they too can make a difference in the global community.

Nav Nidhi Rajput, PhD

A team of researchers led by Nav Nidhi Rajput, PhD, at Stony Brook University, have found a way to computationally predict stable molecular species in liquid solutions. The new method, detailed in a paper in Nature Computational Science, introduces a fully automated high-throughput computational framework to predict stable species by computing their nuclear magnetic resonance (NMR) chemical shifts.

Liquid solutions are essential aspects of both materials science applications such as battery development, and biological applications such as drug discovery. However, to optimize the performance of liquid applications, an understanding of the structure and thermodynamic stability and transport of any chemical species in a solution is paramount. Rajput and colleagues used NMR as a powerful technique to develop an atomistic view to predict stable species.

“Elucidating the complex solvation environment in multi-component liquid solutions can be a daunting task, even by using advanced experimental and computational techniques,” explains Rajput, Assistant Professor in the Department of Materials Science and Chemical Engineering in the College of Engineering and Applied Sciences. “We combined density functional theory with classical molecular dynamics simulations to make our predictions via NMR.”

The researchers developed and tested a computational framework that through simulations robustly and efficiently calculates, analyses, and stores NMR chemical shifts from a variety of molecules in liquid solutions. They also say the framework addresses some of the most challenging aspects of computational NMR by eliminating intuition driven prediction of stable species in liquid solutions.

They add that data collected from this framework should provide fingerprints to guide future experimental investigations of liquid solutions that have optimal properties for material and science applications.

For more details and a further explanation of the research method and the implications of the work, see this research briefing.

The work also involved use of key computational resources at Stony Brook’s Institute for Advanced Computational Science (IACS).

Photo: Nav Nidhi Rajput, PhD

Famotidine molecule Image courtesy of Wikipedia

By Daniel Dunaief

An over-the-counter stomach-soothing medication may also relieve some of the symptoms of mild to moderate COVID-19.

Tobias Janowitz Photo courtesy of CSHL

In a study recently published in the journal Gut, Cold Spring Harbor Laboratory Assistant Professor Tobias Janowitz and a team of collaborators at CSHL and The Feinstein Institutes for Medical Research at Northwell Health demonstrated that Famotidine, the active ingredient in Pepcid, shortened the duration of symptoms for a diverse patient group of adults soon after developing COVID-19 symptoms.

In a placebo-controlled study, people taking 80 milligrams of Famotidine three times a day reported that symptoms such as headaches declined after 8.2 days, compared with 11.4 days for patients who were taking the placebo.

“We think that the results are preliminary, but encouraging,” Janowitz explained in an email. 

The research, which included 55 volunteers, may offer health care providers another tool to help treat mild to moderate cases of COVID-19. In the clinical study, the use of Famotidine helped reduce a potentially overactive inflammatory response without suppressing the immune system’s efforts to ward off the virus.

Participants in the study received Famotidine or placebo pills along with a host of instruments they could use at home to gather clinical data about themselves, including a cellular activated Apple iPad, a scale, thermometer, fitness tracker, spirometer to measure air flow in and out of the lungs and a pulse oximeter, which measured oxygen levels by taking a reading over a person’s fingernails.

The protocol for the study allowed volunteers to stay home, where they gathered results from the instruments and reported on their health and any symptoms they felt. Technicians came to the home of each volunteer on the first, seventh, 15th, and 28th days after entering the clinical trial.

Researchers and doctors involved in the analysis of the effectiveness of COVID believe this remote approach to participating in clinical trials could prove a safe and effective way to conduct research for other diseases.

“In today’s virtual world, our clinical trial strategy has significant implications for how to study new drugs in patients at home,” Dr. Kevin Tracey, president and CEO of the Feinstein Institutes, explained in a Cold Spring Harbor Laboratory news brief.

Janowitz added that other studies could also use testing protocols at home, including for other diseases. “We are looking forward to employing it to help develop better treatments for people with cancer,” which is the disease at the center of his research, he explained.

The CSHL Assistant Professor focuses on the whole body response to cancer, although many of the biological considerations are transferable to other diseases.

Pivot to COVID

According to Janowitz, “It was relatively easy for us to pivot to COVID research when it was a global area of unmet need.” 

The researchers chose Famotidine because of encouraging studies and from a case series, Janowitz explained. They also found a potential mechanism of action where Famotidine blocked the H2 receptor, which encouraged them to move to a phase 2 randomized clinical trial.

The researchers were pleased that the participants in this small trial included people from a range of ages and ethnic groups. Nearly two thirds of patients, who were 18 years and older, were from black, mixed-race or Hispanic communities.

“Patients with different ancestry may have different responses to this disease,” Janowitz explained. “It helps to learn about the generalizability of the results.”

In a CSHL news brief, Nicole Jordan-Martin, executive director for New York City Health + Hospitals, added that “accessible, safe and low-cost outpatient treatment options are a priority in our global efforts to combat COVID-19.” Northwell and New York City Health + Hospitals provided care for the communities most in need of support for New York City, she added.

The collaborators were also encouraged by their teamwork.

“Our institutions worked extremely well together to face challenges the pandemic posed, like offering digital solutions and reaching populations who struggled for access to care,” Dr. Christina Brennan, vice president of clinical research at the Feinstein Institute and co-investigator of the trial, said in the news brief. 

“From screening patients to organizing home delivery of the equipment and medication, this sets a new model for future trials and convenience for participants.”

Janowitz described the safety profile of Famotidine as “excellent” and said it “appears to have few interactions with other drugs and very few side effects in general.”

To be sure, Janowitz cautioned doctors and patients not to stock up on Famotidine before researchers conduct additional studies.

“Our trial is not conclusive and an early phase clinical trial (phase 1 or 2) is not sufficient to inform clinical practice,” he wrote.

Additionally without further study, researchers don’t know the best potential dose and dosing interval for this possible treatment. At this point, they know how long the drug stays in the blood and the strength of its binding to its receptor.

A dose of 20 milligrams per day or less may be too little to achieve an effect, but “we do not know this for certain,” Janowitz explained.

While researchers agreed that further studies were necessary to answer key questions, they believed that the results from this research could provide fodder for studies outside of the COVID world.

“It is possible that sustained inflammation contributes to illness in other contexts and changing this inflammation would be beneficial,” Janowitz wrote. “This will have to be explored separately. Importantly, the methods used in this trial are also transferrable, so we have learned a lot of important information” from this research.

The U.S. Department of Energy’s (DOE) Brookhaven National Laboratory has awarded a $61.8 million contract to Plainview, NY-based E.W. Howell to build the Lab‘s new Science and User Support Center (SUSC). This new facility is part of a larger effort to redevelop an existing on-site apartment area near Brookhaven Lab‘s entryway. General contractor E.W. Howell will oversee SUSC construction, planned to start in the first quarter of 2022.

With approximately 75,000 gross square feet, the SUSC will serve as a welcome center for guests, researchers, and facility users arriving at Brookhaven Lab. It will offer modern, configurable conference space for scientists to collaborate and office areas for Lab employees.

The future Science and User Support Center

The SUSC is the first building planned for Discovery Park, a new vision for the gateway to Brookhaven Lab. The concept for Discovery Park includes the potential for additional development on approximately 60 acres of previously used, publicly accessible land. The Lab is working, in coordination with DOE, on a process for developers, collaborators, and entrepreneurs to propose, build, and operate new facilities in Discovery Park. Future occupants will complement the DOE and Brookhaven Lab missions, leveraging opportunities that result from close proximity to the Laboratory. Discovery Park will offer a flexible platform to advance science and technology-based economic development for Long Island, New York State, and beyond.

Brookhaven Lab‘s 5,321-acre site is located north of the Long Island Expressway near Exit 68 and east of the William Floyd Parkway. The SUSC and Discovery Park will be built off William Floyd Parkway along the access road leading to Brookhaven Lab‘s main entrance.

The selection of E.W. Howell as general contractor follows DOE’s decision on Sept. 13, 2021, approving a total project cost of $86.2 million and awarding the Lab‘s SUSC project team with “Critical Decision Three” (CD-3). CD-3 is the fourth major milestone in DOE’s five-step project management process. The SUSC project team—comprising staff from Brookhaven Lab and the DOE’s local Brookhaven Site Office—and E.W. Howell are targeting summer 2024 for SUSC construction to be completed.

The SUSC was designed by Burns & McDonnell and Gensler, two U.S.-based international firms.

Significant investment supporting science and technology

The Science and User Support Center will serve as a welcome center for guests, researchers, and facility users arriving at Brookhaven Lab. It will offer modern, configurable conference space for scientists to collaborate and office areas for Lab employees.

“The Department of Energy’s investment in the Science and User Support Center reflects our commitment to science and technology for the nation. It represents a significant step towards moving Brookhaven National Laboratory’s outwardly facing organizations closer and more accessible to the public. DOE continues to support the SUSC to improve researchers’ access to the experts and capabilities offered at Brookhaven Lab,” said Robert Gordon, manager of DOE’s local Brookhaven Site Office.

“Awarding this contract marks a major milestone in Brookhaven Lab‘s efforts to improve experiences for staff, guests, and users, to modernize infrastructure, and increase the Laboratory’s overall impact,” said Jack Anderson, Deputy Director for Operations at the Lab. “We’re excited for the facility and for the scientific collaborations it will help facilitate.”

Future first destination for thousands of visiting scientists
More than 5,000 guests traveled to Brookhaven Lab annually in the years before the COVID-19 pandemic. The largest percentage came from institutions in New York State, but many came from across the country and around the world, attracted by the Lab‘s in-house experts and highly specialized research facilities for experiments. Those facilities include DOE Office of Science User Facilities such as the Relativistic Heavy Ion Collider, National Synchrotron Light Source II, and Center for Functional Nanomaterials. Guests also visited—sometimes hundreds at a time—for conferences, workshops, and other events to discuss scientific results and opportunities for future research.

Because of the ongoing pandemic, research collaborations are continuing with remote access and few guests traveling to Brookhaven Lab. When it becomes safer for the Laboratory to return to more normal operations, many guests and facility users are expected to return to the Lab site. Upon completion, the SUSC will be their first destination on site upon arrival at the Laboratory.

The SUSC project is funded by the DOE Office of Science.

Brookhaven National Laboratory is supported by the Office of Science of the U.S. Department of Energy. The Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit science.energy.gov.

METRO image

Stay connected! The Smithtown Historical Society hosts a Technology Savvy Seniors program at the Brush Barn, 211 E. Main St., Smithtown every other Friday including March 11 and 25 at 10 a.m. This free technology workshop is geared to help seniors with their cell phones, tablets, laptops and more. Topic will vary at each session. Call 631-265-6768 for further details.

Jose M. Adrover and Mikala Egeblad. Photo by Lijuan Sun

By Daniel Dunaief

Cold Spring Harbor Laboratory Professor Mikala Egeblad thought she saw something familiar at the beginning of the pandemic.

Mikala Egeblad. Photo from CSHL

Egeblad has focused on the way the immune system’s defenses can exacerbate cancer and other diseases. Specifically, she studies the way a type of white blood cell produces an abundance of neutrophil extracellular traps or NETs that can break down diseased and healthy cells indiscriminately. She thought potentially high concentrations of these NETs could have been playing a role in the worst cases of COVID.

“We got the idea that NETs were involved in COVID-19 from the early reports from China and Italy” that described how the sickest patients had severe lung damage, clotting events and damage to their kidneys, which was what she’d expect from overactive NETs, Egeblad explained in an email.

Recently, she, her post doctoral researcher Jose M. Adrover and collaborators at Weill Cornell Medical College and the Icahn School of Medicine at Mt. Sinai proved that this hypothesis had merit. They showed in hamsters infected with COVID and in mice with acute lung injuries that disabling these NETs improved the health of these rodents, which strongly suggested that NETs are playing a role in COVID-19.

“It was very exciting to go from forming a hypothesis to showing it was correct in the context of a complete new disease and within a relatively short time period,” Egeblad wrote.

Egeblad, Andover and their collaborators recently published their work in the Journal of Clinical Investigation Insight.

Importantly, reducing the NETs did not alter how much virus was in the lungs of the hamsters, which suggests that reducing NETs didn’t weaken the immune system’s response to the virus.

Additional experiments would be necessary to prove this is true for people battling the worst symptoms of COVID-19, Egeblad added.

While the research is in the early stages, it advances the understanding of the importance of NETs and offers a potential approach to treating COVID-19.

An unexpected direction

Jose Adrover. Photo from CSHL

When Adrover arrived from Spain, where he had earned his PhD from the Universidad Complutense de Madrid and had conducted research as a post doctoral fellow at the Spanish Center for Cardiovascular Research in March of 2020, he expected to do immune-related cancer research.

Within weeks, however, the world changed. Like other researchers at CSHL and around the world, Egeblad and Adrover redirected their efforts towards combating COVID.

Egeblad and Andover “were thinking about the virus and what was going on and we thought about trying to do something,” Adrover said. 

Egeblad and Adrover weren’t trying to fight the virus but rather the danger from overactive NETs in the immune system.

Finding an approved drug

Even though they were searching for a way to calm an immune system responding to a new threat, Egeblad and Adrover hoped to find a drug that was already approved.

After all, the process of developing a drug, testing its safety, and getting Food and Drug Administration approval is costly and time-consuming. 

That’s where Juliane Daßler-Plenker, also a postdoctoral fellow in Egeblad’s lab, came in. Daßler-Plenker conducted a literature search and found disulfiram, a drug approved in the 1950’s to treat alcohol use disorder. Specifically, she found a preprint reporting that disulfuram can target a key molecule in macrophages, which are another immune cell. Since the researchers knew this was important for the formation of NETs, Daßler-Plenker proposed that the lab test it.

Working with Weill Cornell Medical College and the Icahn School of Medicine at Mt. Sinai, Adrover explored the effect of disulfiram, among several other possible treatments, on NET production.

Using purified neutrophils from mice and from humans, Adrover discovered that disulfiram was the most effective treatment to block the formation of NETs.

He, Assistant Professor Robert Schwartz’s staff at Weill Cornell and Professor Benjamin tenOever at Mt. Sinai tried disulfiram on hamsters infected with SARS-Cov-2. The drug blocked net production and reduced lung injury.

The two experiments were “useful in my opinion as it strengthens our results, since we blocked NETs and injury in two independent models, one of infection and the other of sterile injury,” Adrover said. “Disulfuram worked in both models.”

More work needed

While encouraged by the results, Egeblad cautioned that this work started before the availability of vaccines. The lab is currently investigating how neutrophils in vaccinated people respond to COVID-19.

Still, this research offered potential promise for additional work on NETs with some COVID patients and with people whose battles with other diseases could involve some of the same immune-triggered damage.

“Beyond COVID, we are thinking about whether it would be possible to use disulfiram for acute respiratory distress syndrome,” Egeblad said. She thinks the research community has focused more attention on NETs.

“A lot more clinicians are aware of NETs and NETs’ role in diseases, COVID-19 and beyond,” she said. Researchers have developed an “appreciation that they are an important part of the immune response and inflammatory response.”

While researchers currently have methods to test the concentration of NETs in the blood, these tests are not standardized yet for routine clinical use. Egeblad is “sensing that there is more interest in figuring out how and when to target NETs” among companies hoping to discover treatments for COVID and other diseases.

The CSHL researcher said the initial race to gather information has proven that NETs are a potentially important target. Down the road, additional research will address a wide range of questions, including what causes some patients to develop different levels of NETs in response to infections.

Esther Takeuchi

Esther S. Takeuchi, PhD, Distinguished Professor and the William and Jane Knapp Chair at Stony Brook University is being honored by the National Academy of Sciences (NAS) and will receive the Award in Chemical Sciences. This award is in recognition of her breakthrough contributions in the understanding of electrochemical energy storage.  

Takeuchi, who holds a joint appointment at Department of Energy’s (DOE) Brookhaven National Laboratory, is an internationally recognized inventor, researcher, and educator in the fields of materials science, chemistry and renewable energy. She will be honored in a ceremony during the NAS 159th annual meeting on May 1 and will receive a medal and prize of $15,000 sponsored by the Merck Company Foundation.

The award cites Takeuchi’s contributions “to the materials and mechanistic understanding relevant to electrochemical energy storage, using chemical insight to address issues of critical importance.”

“I am sincerely honored to receive the National Academy of Science Award for Chemical Sciences,” said Takeuchi, also the Knapp Chair Professor of Energy and the Environment in the Department of Materials Science and Chemical Engineering “The fundamental chemistry of electrochemical energy storage is complex and the subsequent development of viable energy storage devices is made even more challenging by the unique demands of each application.”

Takeuchi’s research has been instrumental in energy storage improvements that meet societal needs and can be applied to electric vehicles, medical devices, and batteries that back up the power grid. Among her numerous and notable inventions is a compact lithium/silver vanadium oxide battery that increased the lifespan of implantable cardiac defibrillators, a solution that reduced the number of surgeries patients needed to undergo to replace the devices that detect and correct irregular, potentially fatal, heart rhythms.

Takeuchi was recently elected a member of the American Academy of Arts and Sciences. She has also been inducted into the National Academy of Engineering and selected as a Fellow of the American Institute for Medical and Biological Engineering and the American Association for the Advancement of Science. She was selected as the 2013 recipient of the E.V. Murphree Award in Industrial and Engineering Chemistry from the American Chemical Society. She was inducted into the National Inventors Hall of Fame in 2011. In 2009, President Obama presented Takeuchi with the National Medal of Technology and Innovation, the highest honor possible for technological achievement in the United States.

Ostrich eggshell beads found at the Mlambalasi site. These beads are examples of Later Stone Age cultural objects that people created and traded as they traveled the continent. Photo by Jennifer Miller

Ancient DNA from the remains of nearly three dozen African foragers—groups associated with hunting, gathering, and fishing—sheds new light on how groups across sub-Saharan Africa lived, traveled and settled prior to the spread of herding and farming. The study involved an international team of 44 researchers including experts from Stony Brook University. The findings, to be published in Nature, produced the earliest DNA of humans on the continent, at some 5,000 to 18,000 years old.

View of the Mlambalasi Rock Shelter in Tanzania, where one of the newly DNA sequenced individuals was recovered by Elizabeth Sawchuk in 2010. Radiocarbon dates suggest that this individual lived approximately 18,000 years ago, making their DNA the oldest currently known in Africa. Photo by Katie Biittner

The new genetic findings add weight to archeological, skeletal and linguistic evidence for changes in how people were moving and interacting across Africa toward the end of the Ice Ages. Around 50,000 years ago, distinct groups of foragers began exhibiting similar cultural traditions, hinting at the development of exchange networks and interregional connections. The reason for this shift, which archaeologists refer to as the Later Stone Age transition, has remained a mystery.

“We demonstrated for the first time that a major archeological transition some 50,000 years ago associated with profound shifts in technology, symbolism, and so-called ‘modern behavior’ in fact coincided with major demographic changes,” said Elizabeth Sawchuk, PhD, Co-First Author, Research Assistant Professor at Stony Brook University and a Banting Postdoctoral Fellow at the University of Alberta. “We found that ancient foragers across eastern and south-central Africa are a mix of eastern, southern, and central African ancestry, showing there was widespread movement and mixing across sub-Saharan Africa coinciding with the transition from the Middle to Later Stone Age.”

Previous research proposed a genetic cline (or gradient) of variation among ancient African foragers extending from eastern to southern Africa. To the research team’s surprise, this new analysis indicates a three-way cline instead of a two-way cline that includes a central African ancestry – a significant point of future investigation because there has been less archeological research in central Africa than other parts of the continent.

“By associating archaeological artifacts with ancient DNA, the researchers have created a remarkable framework for exploring the prehistory of humans in Africa,” says Archaeology and Archaeometry program director John Yellen of the U.S. National Science Foundation, one of the funders behind this project. “This insight is charting a new way forward to understanding humanity and our complex shared history.”

Sawchuk and Stony Brook colleague and Co-Author Jason Lewis, PhD, presented ancient DNA (aDNA) from six individuals from the Late Pleistocene and early Holocene from five sites in Tanzania, Zambia, and Malawi

These six individuals have now yielded the oldest human DNA from sub-Saharan Africa.

The six individuals were analyzed with 28 previously published ancient persons associated with foraging and/or Later Stone Age material culture. The research team also generated higher coverage data for fifteen of these individuals which permitted a more in-depth look at their DNA.

Lewis co-led a team reanalyzing the history of work and collections from the ancient Tanzanian rockshelter site of Kisese II, particularly in the context and dating of the human remains, allowing the collection to be included in the present study. The skeletons from the site were originally excavated in the 1960s but remained unstudied until recently.

“The work is a great example of the unexpected and important results that can come from going back to old museum collections to take another look with new approaches and technologies, in this case using aDNA methods,” said Lewis.

Ancient DNA and archaeological data now both point toward a demographic transition across Africa around the time that beads, pigments, and symbolic art became more widespread. Sawchuk, Lewis and colleagues note that while scientists have proposed shifts in social networks and perhaps changes in populations sizes played a role, such hypotheses have remained difficult to test.

“We’ve never been able to directly explore proposed demographic shifts until now,” explains Sawchuk. “It has been difficult to reconstruct events in our deeper past using the DNA of people living today, and artifacts can’t tell the whole story. The DNA from people who lived around this time provides the missing piece of the puzzle, offering an unprecedented view of population structures among ancient foragers.”

While this three-way population structure can only be explained by widespread movement and mixing in the past, the researchers also note that the traveling and mixing didn’t last.

Individuals in this study were most genetically similar to their geographic neighbors, which suggests that by 20,000 years ago, people had already stopped moving as much. The authors explain this coincides with archaeological evidence for “regionalization” toward the end of the Ice Ages when Later Stone Age industries began to diversity and take on distinctive local attributes. So while stone and beads continued moving through exchange networks, people themselves began living more locally.

Mary Prendergast, the study’s co-Senior Author and Associate Professor of Anthropology at Rice University, said there are arguments that the development and expansion of long-distance trade networks around these ancient times helped humans weather the last Ice Age.

“Humans began relying on each other in new ways,” she said. “And this shift in how people interacted with one another may have been what allowed people to thrive.

“The work also helps address the global imbalance of research, as there are around 30 times more published ancient DNA sequences from Europe than from Africa,” she added. “Given that Africa harbors the greatest human genetic diversity on the plant, we have much more to learn.”

The entire research team included scholars from the United States, Canada, Kenya, Malawi, Tanzania, Zambia and several other countries. Critical contributions to the study came from curators and co-authors from African museums who are responsible for protecting and preserving the remains.